23.99
+0.01(+0.04%)
Currency In USD
| Previous Close | 23.98 |
| Open | 23.95 |
| Day High | 24.32 |
| Day Low | 23.92 |
| 52-Week High | 27.64 |
| 52-Week Low | 18.17 |
| Volume | 416,235 |
| Average Volume | 627,123 |
| Market Cap | 1.09B |
| PE | 51.04 |
| EPS | 0.47 |
| Moving Average 50 Days | 23.16 |
| Moving Average 200 Days | 24.33 |
| Change | 0.01 |
If you invested $1000 in Pacira BioSciences, Inc. (PCRX) 10 years ago, it would be worth $385.51 as of December 07, 2025 at a share price of $23.99. Whereas If you bought $1000 worth of Pacira BioSciences, Inc. (PCRX) shares 5 years ago, it would be worth $399.77 as of December 07, 2025 at a share price of $23.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported -- BRISBA
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
GlobeNewswire Inc.
Nov 26, 2025 9:01 PM GMT
-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to t
Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
GlobeNewswire Inc.
Nov 05, 2025 1:00 PM GMT
-- Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory IL-1Ra production in the knee joint -- BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nas